Tag: Intensity Therapeutics

June 26, 2019 Off

Intensity Therapeutics to work with Merck on its lead prduct combined with Keytruda

Phase 1/2 clinical trial to evaluate Intensity’s INT230-6 in combination with KEYTRUDA® (pembrolizumab) for multiple solid tumor types

May 16, 2019 Off

Intensity Therapeutics to Present Data on Safety, Tumor Regression and Immune Activation of INT230-6 at ASCO 2019

By BusinessWire

WESTPORT, Conn.–(BUSINESS WIRE)–Intensity Therapeutics, Inc., a clinical-stage biotechnology company pioneering a novel, immune-based approach to treat solid tumor cancers through…